Rounds: “Risk – Benefit Analysis with Incretin Therapy in Type2 Diabetes
James Lane, MD, Professor & Section Chief, Department of Medicine/Endocrinology
Upon completion of this activity, participants will be able to: Identify the complications of incretin therapy noted in animal and human studies. To identify potential mechanisms for the above noted complications. To evaluate the adequacy fo human data in answering the question of safety in human subjects in incretin therapy.
For more information contact:
Department of Medicine/Endocrinology and Diabetes